Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neur… Read more
Neurizon Therapeutics Ltd (NUZ) - Net Assets
Latest net assets as of June 2025: AU$2.82 Million AUD
Based on the latest financial reports, Neurizon Therapeutics Ltd (NUZ) has net assets worth AU$2.82 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$4.36 Million) and total liabilities (AU$1.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$2.82 Million |
| % of Total Assets | 64.71% |
| Annual Growth Rate | -1.46% |
| 5-Year Change | -64.04% |
| 10-Year Change | -59.21% |
| Growth Volatility | 166.12 |
Neurizon Therapeutics Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Neurizon Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neurizon Therapeutics Ltd (2001–2025)
The table below shows the annual net assets of Neurizon Therapeutics Ltd from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.82 Million | -72.42% |
| 2024-06-30 | AU$10.23 Million | +163.00% |
| 2023-06-30 | AU$3.89 Million | -0.19% |
| 2022-06-30 | AU$3.90 Million | -50.33% |
| 2021-06-30 | AU$7.84 Million | -11.67% |
| 2020-06-30 | AU$8.88 Million | +4.15% |
| 2019-06-30 | AU$8.53 Million | +14.36% |
| 2018-06-30 | AU$7.46 Million | +4.45% |
| 2017-06-30 | AU$7.14 Million | +3.23% |
| 2016-06-30 | AU$6.92 Million | +37.66% |
| 2015-06-30 | AU$5.02 Million | -43.17% |
| 2014-06-30 | AU$8.84 Million | +13.84% |
| 2013-06-30 | AU$7.76 Million | +327.98% |
| 2012-06-30 | AU$1.81 Million | +611.69% |
| 2011-06-30 | AU$254.90K | -77.79% |
| 2010-06-30 | AU$1.15 Million | -80.23% |
| 2009-06-30 | AU$5.81 Million | -0.84% |
| 2008-06-30 | AU$5.86 Million | -0.97% |
| 2007-06-30 | AU$5.91 Million | -23.06% |
| 2006-06-30 | AU$7.69 Million | 0.00% |
| 2005-06-30 | AU$7.69 Million | +98.70% |
| 2004-06-30 | AU$3.87 Million | +422.03% |
| 2003-06-30 | AU$741.02K | -78.64% |
| 2002-06-30 | AU$3.47 Million | -13.47% |
| 2001-06-30 | AU$4.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurizon Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7588335700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$78.80 Million | 2793.78% |
| Other Comprehensive Income | AU$2.00 Million | 70.84% |
| Total Equity | AU$2.82 Million | 100.00% |
Neurizon Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Neurizon Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LB30
F:LB30
|
$18.06 Million |
|
De Nora India Limited
NSE:DENORA
|
$18.07 Million |
|
Fang Holdings Ltd
NYSE:SFUNY
|
$18.07 Million |
|
Innovate Corp
NYSE:VATE
|
$18.08 Million |
|
Ascent Solar Technologies, Inc. Common Stock
NASDAQ:ASTI
|
$18.06 Million |
|
New Advanced Electronics Technologies Co Ltd
TWO:3465
|
$18.05 Million |
|
DVL Inc
PINK:DVLN
|
$18.05 Million |
|
Cassiar Gold Corp
OTCQX:CGLCF
|
$18.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurizon Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,228,243 to 2,820,571, a change of -7,407,672 (-72.4%).
- Net loss of 16,593,619 reduced equity.
- Other comprehensive income decreased equity by 2,426,675.
- Other factors increased equity by 11,612,622.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-16.59 Million | -588.31% |
| Other Comprehensive Income | AU$-2.43 Million | -86.03% |
| Other Changes | AU$11.61 Million | +411.71% |
| Total Change | AU$- | -72.42% |
Book Value vs Market Value Analysis
This analysis compares Neurizon Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 12.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-06-30 | AU$4.93 | AU$0.08 | x |
| 2002-06-30 | AU$3.22 | AU$0.08 | x |
| 2003-06-30 | AU$0.50 | AU$0.08 | x |
| 2004-06-30 | AU$2.05 | AU$0.08 | x |
| 2005-06-30 | AU$2.29 | AU$0.08 | x |
| 2006-06-30 | AU$1.69 | AU$0.08 | x |
| 2007-06-30 | AU$0.95 | AU$0.08 | x |
| 2008-06-30 | AU$0.49 | AU$0.08 | x |
| 2009-06-30 | AU$0.42 | AU$0.08 | x |
| 2010-06-30 | AU$0.40 | AU$0.08 | x |
| 2011-06-30 | AU$0.07 | AU$0.08 | x |
| 2012-06-30 | AU$0.05 | AU$0.08 | x |
| 2013-06-30 | AU$0.01 | AU$0.08 | x |
| 2014-06-30 | AU$0.13 | AU$0.08 | x |
| 2015-06-30 | AU$0.12 | AU$0.08 | x |
| 2016-06-30 | AU$0.05 | AU$0.08 | x |
| 2017-06-30 | AU$0.06 | AU$0.08 | x |
| 2018-06-30 | AU$0.05 | AU$0.08 | x |
| 2019-06-30 | AU$0.03 | AU$0.08 | x |
| 2020-06-30 | AU$0.03 | AU$0.08 | x |
| 2021-06-30 | AU$0.03 | AU$0.08 | x |
| 2022-06-30 | AU$0.02 | AU$0.08 | x |
| 2023-06-30 | AU$0.01 | AU$0.08 | x |
| 2024-06-30 | AU$0.03 | AU$0.08 | x |
| 2025-06-30 | AU$0.01 | AU$0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurizon Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -588.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.55x
- Recent ROE (-588.31%) is below the historical average (-116.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -52.23% | 0.00% | 0.00x | 1.24x | AU$-2.50 Million |
| 2002 | -106.78% | -1190.76% | 0.06x | 1.42x | AU$-4.05 Million |
| 2003 | -314.65% | -676.48% | 0.34x | 1.37x | AU$-2.14 Million |
| 2004 | 0.95% | 1.15% | 0.61x | 1.36x | AU$-349.98K |
| 2005 | -35.81% | -45.08% | 0.67x | 1.19x | AU$-3.52 Million |
| 2006 | -35.81% | -45.08% | 0.67x | 1.19x | AU$-3.52 Million |
| 2007 | -60.97% | -133.74% | 0.34x | 1.35x | AU$-4.20 Million |
| 2008 | -3.04% | -11.48% | 0.21x | 1.28x | AU$-771.02K |
| 2009 | -3.07% | -10.23% | 0.26x | 1.17x | AU$-765.26K |
| 2010 | -7.55% | -26.73% | 1.13x | 0.25x | AU$-1.02 Million |
| 2011 | -371.16% | -274.43% | 1.07x | 1.26x | AU$-4.38 Million |
| 2012 | -351.30% | -263.34% | 0.67x | 1.99x | AU$-4.38 Million |
| 2013 | -423.91% | -70.07% | 0.23x | 26.41x | AU$-1.35 Million |
| 2014 | -21.78% | -102.99% | 0.20x | 1.08x | AU$-2.81 Million |
| 2015 | -44.43% | -194.62% | 0.32x | 0.71x | AU$-4.81 Million |
| 2016 | -26.75% | -47.08% | 0.35x | 1.63x | AU$-1.85 Million |
| 2017 | -36.47% | -87.82% | 0.34x | 1.21x | AU$-3.21 Million |
| 2018 | -21.73% | -42.26% | 0.43x | 1.20x | AU$-2.27 Million |
| 2019 | -18.27% | -42.62% | 0.30x | 1.44x | AU$-2.11 Million |
| 2020 | -15.97% | -42.62% | 0.29x | 1.28x | AU$-2.21 Million |
| 2021 | -19.24% | -50.52% | 0.34x | 1.13x | AU$-2.60 Million |
| 2022 | -21.78% | -50.52% | 0.55x | 0.78x | AU$-2.49 Million |
| 2023 | -232.25% | -319.85% | 0.46x | 1.58x | AU$-9.42 Million |
| 2024 | -88.31% | 0.00% | 0.00x | 1.09x | AU$-10.06 Million |
| 2025 | -588.31% | 0.00% | 0.00x | 1.55x | AU$-16.88 Million |
Industry Comparison
This section compares Neurizon Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurizon Therapeutics Ltd (NUZ) | AU$2.82 Million | -52.23% | 0.55x | $18.06 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |